Primary Treatment with Molecular-Targeted Agents for Hepatocellular Carcinoma: A Propensity Score-matching Analysis.
Journal
Hepatology communications
ISSN: 2471-254X
Titre abrégé: Hepatol Commun
Pays: United States
ID NLM: 101695860
Informations de publication
Date de publication:
Aug 2020
Aug 2020
Historique:
received:
02
03
2020
revised:
13
04
2020
accepted:
28
04
2020
entrez:
9
8
2020
pubmed:
9
8
2020
medline:
9
8
2020
Statut:
epublish
Résumé
Sorafenib and lenvatinib, as molecular-targeted agents, constitute effective primary treatment options for advanced hepatocellular carcinoma (HCC). However, the choice of optimal primary treatment agent remains controversial. Here, we aimed to assess the respective outcomes between these agents as primary treatment in patients with advanced HCC through use of propensity score-matching analysis (PSMA). We enrolled 670 consecutive patients who were diagnosed with advanced HCC and received sorafenib (n = 524) or lenvatinib (n = 146) as the primary treatment among 18 participating institutions between May 2009 and October 2019. To reduce confounding, we used PSMA regarding seven variables related to advanced HCC prognosis, resulting in the selection of 292 patients (n = 146 for each agent). Following PSMA, no significant difference was observed in the outcome of overall survival time between patients treated with sorafenib or lenvatinib (median survival time 15.3 or 14.9 months, respectively;
Identifiants
pubmed: 32766480
doi: 10.1002/hep4.1535
pii: HEP41535
pmc: PMC7395064
doi:
Types de publication
Journal Article
Langues
eng
Pagination
1218-1228Informations de copyright
© 2020 The Authors. Hepatology Communications published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.
Références
Lancet Oncol. 2019 Feb;20(2):282-296
pubmed: 30665869
Lancet Oncol. 2009 Jan;10(1):25-34
pubmed: 19095497
Biologics. 2014 Apr 10;8:129-39
pubmed: 24748771
Stat Med. 1998 Oct 15;17(19):2265-81
pubmed: 9802183
Invest New Drugs. 2015 Jun;33(3):729-39
pubmed: 25861764
Liver Cancer. 2019 Mar;8(2):130-139
pubmed: 31019903
Surg Oncol. 2016 Jun;25(2):74-85
pubmed: 27312032
Lancet. 2017 Jan 7;389(10064):56-66
pubmed: 27932229
N Engl J Med. 2015 Feb 12;372(7):621-30
pubmed: 25671254
J Hepatol. 2019 Jun;70(6):1262-1277
pubmed: 30943423
J Hepatol. 2012 Oct;57(4):821-9
pubmed: 22727733
J Gastroenterol. 2017 Apr;52(4):512-519
pubmed: 27704266
Rheum Dis Clin North Am. 2018 May;44(2):203-213
pubmed: 29622292
J Clin Oncol. 2013 Oct 1;31(28):3509-16
pubmed: 23980090
N Engl J Med. 2008 Jul 24;359(4):378-90
pubmed: 18650514
Support Care Cancer. 2016 Aug;24(8):3669-76
pubmed: 27260018
Ann Oncol. 2015 Dec;26(12):2457-63
pubmed: 26386123
J Natl Cancer Inst. 2014 Sep 29;106(9):
pubmed: 25265940
Oral Oncol. 2012 Jun;48(6):554-9
pubmed: 22289637
J Clin Oncol. 2005 Dec 20;23(36):9441-2
pubmed: 16361649
Int J Cancer. 2008 Feb 1;122(3):664-71
pubmed: 17943726
J Clin Oncol. 2013 Oct 1;31(28):3517-24
pubmed: 23980084
Semin Liver Dis. 1999;19(3):329-38
pubmed: 10518312
Semin Liver Dis. 2010 Feb;30(1):61-74
pubmed: 20175034
Dig Dis. 2014;32(6):705-10
pubmed: 25376287
N Engl J Med. 2018 Jul 05;379(1):54-63
pubmed: 29972759
Liver Cancer. 2019 Nov;8(6):457-467
pubmed: 31799203
J Clin Oncol. 2015 Feb 20;33(6):550-8
pubmed: 25512453
Clin Oncol (R Coll Radiol). 2017 May;29(5):316-324
pubmed: 28318881
Lancet. 2018 Mar 24;391(10126):1163-1173
pubmed: 29433850
J Clin Oncol. 2015 Jan 10;33(2):172-9
pubmed: 25488963
Semin Liver Dis. 2010 Feb;30(1):52-60
pubmed: 20175033
Cancer Sci. 2015 Dec;106(12):1714-21
pubmed: 26426092
Semin Diagn Pathol. 2017 Mar;34(2):153-159
pubmed: 28108047
Hepatol Res. 2016 Jun;46(7):650-6
pubmed: 26441378
Nat Biotechnol. 2008 Jan;26(1):127-32
pubmed: 18183025
Ann Oncol. 2016 May;27(5):856-61
pubmed: 26884590
J Clin Oncol. 2013 Nov 10;31(32):4067-75
pubmed: 24081937
Lancet Oncol. 2015 Jul;16(7):859-70
pubmed: 26095784
J Hepatol. 2001 Sep;35(3):421-30
pubmed: 11592607
Cancer Res. 2004 Oct 1;64(19):7099-109
pubmed: 15466206
Stat Med. 2013 Jul 20;32(16):2837-49
pubmed: 23239115
Anticancer Res. 2015 Jun;35(6):3415-21
pubmed: 26026104
Lancet Oncol. 2018 May;19(5):682-693
pubmed: 29625879